ArticleMarine biotechnology (New York, N.Y.)2026
Neoagarotetraose from Marine Red Algae Ameliorates UVB-Induced Skin Barrier Damage in Mice and HaCaT Keratinocytes.
Article in Marine biotechnology (New York, N.Y.), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Ultraviolet B (UVB) radiation is a major environmental threat that disrupts skin integrity and drives inflammatory skin disorders. Neoagarotetraose (NA4), a low-molecular-weight oligosaccharide derived from marine red algae, is characterized by high bioavailability and well-documented anti-inflammatory properties, yet its role in UVB-induced skin damage remains unexplored. In this study, we investigated the reparative effects of NA4 and its underlying mechanisms using UVB-irradiated HaCaT keratinocytes and C57BL/6 mouse models, with focus on cytotoxicity, cell viability, barrier protein expression, pro-inflammatory cytokines, and MAPK pathway activation. Our results demonstrate that NA4 was non-cytotoxic and dose-dependently restored the viability of UVB-damaged keratinocytes. Notably, NA4 reestablished the expression of key barrier proteins (FLG, ZO-1, COL-I) and corrected UVB-induced elevation of aquaporin-3 (AQP3), while concurrently suppressing pro-inflammatory cytokines (TNF-α, IL-6, IL-1β) and inhibiting the phosphorylation of JNK, ERK1/2, and p38 in both cell and animal models. In vivo, the 2 mg/cm² NA4 treatment achieved superior barrier restoration and anti-inflammatory effects compared to vitamin C. Collectively, these findings identify NA4 as a concentration-dependent, multi-target marine-derived oligosaccharide that concurrently exerts MAPK-mediated anti-inflammatory activity and barrier-restorative effects, offering a mechanistic basis for developing next-generation marine therapeutics against UVB-induced skin damage.
Indexed as
Identifiers
42240706What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.